Aim. Study of multi-year sales statistics in pharmacy market segment to assess the volume and structure of consumed cardiovascular and antithrombotic drugs under COVID-19 pandemic conditions. Material and methods. Data on nomenclature and sales volumes of drugs in pharmacy segment of Samara region in 20152020. Results. It is shown that the share of basic cardiovascular drugs in physical terms is insignificant (5.2-3%). The largest volume of sales are drugs of angiotensin-converting enzyme inhibitor group (28%) and b-adrenoblockers (23.5%). Fixed combinations of hypotensive drugs account for only 13% of the volume of sold basic cardiovascular drugs, and the share of statins is 7.6%, which does not correspond to their role as the most effective drugs in primary and secondary cardiac prevention. The share of antithrombotic drugs in total sales in volume terms was 0.45% in 20152019. In absolute terms, sales of anticoagulants and disaggregants increased in 20182020, which was accompanied by an average 15% increase in the cost per daily dose. Among disaggregants, acetylsalicylic acid (66.6%), clopidogrel (21.6%), and dipyridamole (10.2%) are most frequently sold. The share of disaggregants in sales fell from 74.8 to 57.6% at the expense of acetylsalicylic acid drugs. In 2020, consumption of dipyridamole increased significantly to 16.6% due to inclusion of the drug in protocols for managing patients with COVID-19. Among anticoagulants, the proportion of new oral medications is characterized by a progressive increase from 7.8% in 2015 to 27% in 2020. During the COVID-19 pandemic, the most demanded group of Xa factor blockers is dominated by apixaban (63.8%), which can be explained by the lower cost (by 16%) of a daily equivalent dose compared to rivaroxaban. Conclusion. Low consumption of basic cardiovascular drugs among the population of Samara region, especially statins and combined hypotensive drugs was observed. During COVID-19 pandemic there was an increase in consumption of antithrombotic drugs, due to dipyridamole and new oral anticoagulants.

Objective: to determine the compliance of antihypertensive drugs consumption with the trends of modern pharmacotherapy.Material and methods. The analysis of the consumption level of antihypertensive drugs, their fixed combinations (FC), as well as statins in the retail sector of the pharmaceutical market of the Samara Region in 2015–2020 was carried out. The material of this retrospective study was information about the nomenclature and volume of drug sales in physical and monetary terms for the period under review in one of the retail pharmacies of the Samara Region. The traditional method of pharmacoepidemiological analysis aimed at studying the correctness, completeness and preferences of drug use in real practice is questionnaires for physicians and patients. The main antihypertensive drugs (diuretics, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, β-blockers) and their FC were selected for the analysis.Results. Long-term use of medications aimed at reducing high blood pressure and hypercholesterolemia is seen as an effective strategy for reducing cardiovascular complications and mortality in both primary and secondary prevention. The analysis of sales of basic cardiological drugs in the pharmacy network segment of the Samara Region in 5-year dynamics showed that the consumption of hypotensive drugs and statins makes up 4.72% of the total item sales, with prevalence of angiotensin-converting enzyme inhibitors (28.0%) and β-blockers (23.5%), with insufficient consumption of FC (23.7%), extremely low sales of statins (7.58%).Conclusion. The structure of the studied segment of the pharmaceutical market is conservative with insufficient positive dynamics in the consumption of effective modern drugs and their FC.

Aim to study the characteristics of the consumption of antihypertensive (AG) drugs in the population of several regions of the Russian Federation the Samara region, the Nizhny Novgorod region and the Republic of Tatarstan. Material and methods. The range of AG drugs sold in the retail pharmaceutical market of the Samara and Nizhny Novgorod regions and the Republic of Tatarstan was selected for the study. To manage the obtained data, we used several methods like structural, comparative, logical, predictive, retrospective, graphic, marketing analysis. The results were processed using the normalization method and methods of mathematical statistics. Results. The monopreparations kept the main share of sales in each region: 90.22% in the Samara region, 90.85% in the Nizhny Novgorod region, and 93.72% in the Republic of Tatarstan). In 2021, the leaders in consumption were ACE inhibitors (28.41%, 26.61% and 32.7%, respectively in each region) and -blockers (25.87%, 29.02% and 21.15%). In total, these two subgroups accounted for more than a half of all monopreparations sold, counted in packages. In the subgroup of fixed combinations, the angiotensin II receptor blockers + diuretic were the most popular, which account for 35.38%, 29.73% and 22.13% of drug sales in this subgroup in the Samara, Nizhny Novgorod regions and the Republic of Tatarstan, respectively. In the subgroup of combined antihypertensive drugs, the multicomponent fixed combinations were among the leaders (10.22%, 8.20%, 12.10%, respectively in each region), however, in the total consumption of antihypertensive drugs, they accounted for less than 1%. Conclusion. This study revealed the features of the consumption of drugs prescribed for arterial hypertension in the Samara and Nizhny Novgorod regions, as well as in the Republic of Tatarstan in 2021. We identified the groups of antihypertensive drugs of most demand and found the leaders within these groups. It was established that there was a relationship between the volume of sales of antihypertensive medicines in physical terms (in packages) in the Samara region for the period 20172021 and the population of this region.

In the Russian Federation, preferential medicine provision is an important component of state assistance to citizens living in various regions. One of the main programs of preferential drug provision is the High-cost Nosologies program, funded by the federal budget. The purpose of the work was to study regional implementations of this program in 21 constituent entities of the Russian Federation for the period from 2018 to 2019. On the basis of a comparative analysis of the performance indicators of the program, differences were revealed in the amount of funding,average medicine costs, as well as actual costs per 1 beneficiary. In 2019, in most constituent entities of the Russian Federation, an increase in the number of beneficiaries was revealed along with a simultaneous increase in the medicine costs, which is due to the inclusion of 5 additional diseases in the list of High-cost Nosologies.

Introduction. The regional programs of the subsidized provision of medicines (RPSPM) implemented in the subjects of the Russian Federation are an important state instrument in the field of medicine provision of citizens. Purpose. To study the features of the implementation of RPSPM in various subjects of the Russian Federation over 2018-2019. Material and methods. During the study, the data provided by the health authorities and the pharmaceutical service of 21 constituent entities of the Russian Federation were processed. Results. The median of funding in the studied subjects of the Russian Federation amounted to 713.1 million rubles in 2018 and 753.1 million rubles in 2019. The average actual costs per one applied beneficiary (± standard error) was 2685 ± 941 rubles in 2018 and 2404 ± 780 rubles in 2019. At the end of 2018, about 22.7 million prescriptions were established to be written out in the analyzed subjects of the Russian Federation within the framework of the RPPPM, at the end of 2019 - about 26.2 million prescriptions. The median cost of one prescription reached 1,327 rubles in 2018 and 2,162 rubles in 2019. Comparative analysis showed that the indicators of the funding volume for the RPSPM per beneficiary per year in different subjects of the Russian Federation differ significantly, the median (interquartile range) in 2018 was 6,704 rubles (3,436-11,576 rubles), in 2019 - 8,166 rubles (4,162-10,211 rubles). Limitations. Taking into account the administrative-territorial division of the Russian Federation, in the study we analyzed data on the implementation of the RPSPM for about 25% of the constituent entities of the Russian Federation with various infrastructural, socio-economic, demographic indicators, which is a fairly reference sample group. Conclusion. Thus, we studied the indicators of the implementation of the RPSPM in 21 subjects of the Russian Federation. During 2018-2019 in the analyzed subjects of the Russian Federation, regional beneficiaries had different opportunities to receive medicine assistance within the framework of the RPSPM.